Pulmonary Arterial Hypertension in Infants

Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. Clinical decisions must always be based on the individual patient's condition, the clinician's judgment, and current medical standards of care. Always consult with a qualified healthcare professional.

Overview

• Definition: Pulmonary Artery Hypertension (PAH) in infants is a condition characterized by abnormally high blood pressure in the arteries that supply blood to the lungs. This elevated pressure, typically defined as a mean pulmonary arterial pressure (mPAP) ≥ 20 mmHg at rest (though hemodynamic definitions vary by age and context, e.g., in neonates, it's relative to systemic pressure), leads to increased resistance to blood flow through the pulmonary circulation. In infants, it can manifest as an acute, severe condition (e.g., Persistent Pulmonary Hypertension of the Newborn - PPHN) or a chronic, progressive disease.
• Epidemiology:
  • Persistent Pulmonary Hypertension of the Newborn (PPHN): Affects approximately 1-2 per 1000 live births. It is more common in full-term or post-term infants.
  • Chronic PAH in Infants: Less common, often associated with other underlying conditions.
    • Associated with Congenital Heart Disease (CHD): Most common cause of chronic PH in infants, prevalence varies widely by CHD type (e.g., large left-to-right shunts).
    • Associated with Bronchopulmonary Dysplasia (BPD): Affects 15-40% of infants with severe BPD.
    • Idiopathic PAH (IPAH) or Heritable PAH (HPAH): Very rare in infants, often presents in later infancy or childhood.
    • Associated with Congenital Diaphragmatic Hernia (CDH): Nearly all infants with CDH have some degree of PH, which can be severe.
• Classification:
  • WHO Clinical Classification (Adapted for Pediatrics): While primarily for older children/adults, it helps categorize chronic forms:
    • Group 1: Pulmonary Arterial Hypertension (PAH): Includes idiopathic, heritable, drug/toxin-induced, associated with connective tissue disease, HIV, portal hypertension, congenital heart disease (repaired simple shunts, small/moderate unrepaired shunts). This group is a primary focus for targeted PAH therapies.
    • Group 2: PH due to Left Heart Disease: Rare in infants without significant CHD, but can occur with severe cardiomyopathies or critical left-sided obstructive lesions.
    • Group 3: PH due to Lung Disease and/or Hypoxia: Common in infants (e.g., Bronchopulmonary Dysplasia [BPD], severe acute respiratory distress syndrome [ARDS], interstitial lung disease, airway obstruction).
    • Group 4: Chronic Thromboembolic PH (CTEPH): Very rare in infants.
    • Group 5: PH with Unclear Multifactorial Mechanisms: Includes metabolic disorders, hematologic disorders (e.g., chronic hemolytic anemia), systemic disorders, or external compression of pulmonary vasculature.
  • Clinical Presentation/Course Classification:
    • Acute/Transitional (PPHN): High PVR persisting after birth, leading to right-to-left shunting.
    • Chronic PH: Ongoing elevated PVR beyond the neonatal period, often progressive.

Pathophysiology

• Mechanism:
  • Normal Neonatal Transition: At birth, a precipitous drop in pulmonary vascular resistance (PVR) occurs due to lung expansion, increased alveolar oxygen tension, and release of vasodilators (e.g., nitric oxide, prostacyclin). This allows blood to flow freely to the lungs.
  • PPHN: Failure of this normal physiologic drop in PVR. Mechanisms include:
    • Pulmonary Vasoconstriction: Increased reactivity and tone of pulmonary arteries due to hypoxia, acidosis, or inflammatory mediators.
    • Vascular Remodeling: Thickening of pulmonary arterial walls (hypertrophy of smooth muscle, endothelial dysfunction) and reduced number of vessels.
    • Underdevelopment/Hypoplasia: Reduced cross-sectional area of the pulmonary vascular bed (e.g., in CDH, severe lung hypoplasia).
  • Chronic PH: Involves a combination of vasoconstriction, dysfunctional endothelial proliferation, and severe structural remodeling (medial hypertrophy, intimal proliferation, adventitial fibrosis, formation of plexiform lesions in severe cases). Underlying causes (e.g., chronic hypoxia from BPD, high flow from CHD shunts) drive these changes, leading to progressive increases in PVR and right ventricular (RV) afterload.
• Risk Factors:
  • PPHN:
    • Perinatal asphyxia: Most common cause.
    • Meconium aspiration syndrome (MAS).
    • Congenital diaphragmatic hernia (CDH).
    • Sepsis/Pneumonia.
    • Hypoxia/Acidosis from any cause.
    • Pulmonary hypoplasia: E.g., due to oligohydramnios.
    • Maternal NSAID use (late pregnancy).
    • Idiopathic.
  • Chronic PAH:
    • Congenital Heart Disease (CHD) with left-to-right shunts: Ventricular septal defects (VSDs), atrial septal defects (ASDs), patent ductus arteriosus (PDA) leading to pulmonary overcirculation.
    • Bronchopulmonary Dysplasia (BPD): Chronic lung disease of prematurity.
    • Congenital Diaphragmatic Hernia (CDH).
    • Airway abnormalities/Obstruction: Tracheomalacia, severe laryngomalacia, chronic aspiration.
    • Genetic syndromes: E.g., Down syndrome, alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV).
    • Metabolic disorders.
    • Chronic hypoventilation/sleep apnea.
• Protective Factors:
  • Adequate antenatal care: Prevention of prematurity, infections.
  • Optimal perinatal resuscitation: Avoiding perinatal asphyxia.
  • Timely diagnosis and management of underlying conditions: E.g., surgical repair of significant CHD shunts before irreversible pulmonary vascular changes occur.
  • Early and optimized management of respiratory distress: Including judicious oxygen use and ventilation strategies in infants with lung disease.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Tachypnea: Rapid breathing.
  • Cyanosis: Bluish discoloration of skin/mucous membranes (central, often differential in PPHN if PDA shunting occurs).
  • Increased Work of Breathing: Nasal flaring, grunting, retractions (subcostal, intercostal, suprasternal).
  • Poor feeding/Feeding intolerance: Due to increased respiratory effort and metabolic demand.
  • Failure to thrive (FTT): In chronic PH.
• Early Signs:
  • Lability of oxygen saturation: Fluctuations in SpO2 with handling, crying, or changes in sleep state.
  • Persistent need for high inspired oxygen concentrations (FiO2).
  • Tachycardia.
  • Weak cry/lethargy.
• Advanced Signs:
  • Severe hypoxemia refractory to oxygen: Sign of significant intrapulmonary or extrapulmonary shunting.
  • Systemic hypotension: Due to RV dysfunction and decreased cardiac output.
  • Hepatomegaly: Due to RV failure.
  • Edema: Peripheral or generalized.
  • Syncope: Rare in infants, but a grave sign if present (usually older children).
  • Respiratory arrest/Cardiovascular collapse.
• Atypical Presentations:
  • Isolated FTT and poor weight gain without overt respiratory distress (especially in chronic PH).
  • Recurrent respiratory infections.
  • Sudden worsening of respiratory status during routine care or minor illness.

Physical Examination

• Inspection:
  • Respiratory distress: Tachypnea, nasal flaring, retractions, grunting.
  • Cyanosis: Central (lips, tongue, trunk) or differential (pre-ductal vs. post-ductal saturation difference >5-10% suggests R-L shunting across PDA).
  • Precordial bulge: May indicate chronic cardiomegaly.
  • Poor growth/FTT.
  • Edema: Dependent edema, puffiness around eyes.
• Palpation:
  • Right ventricular heave/lift: Palpable impulse over the left lower sternal border, indicating RV hypertrophy.
  • Hepatomegaly: Liver edge palpable below the costal margin.
  • Bounding pulses: If significant PDA with left-to-right shunt (before PH develops) or other systemic shunts.
• Special Tests:
  • Auscultation:
    • Heart murmurs: May indicate underlying CHD (e.g., holosystolic murmur of VSD, continuous murmur of PDA).
    • Accentuated P2: Loud second heart sound component (pulmonic valve closure) indicating increased pulmonary arterial pressure.
    • Gallop rhythm: S3 or S4, indicative of ventricular dysfunction.
    • Tricuspid regurgitation murmur: Holosystolic murmur loudest at left lower sternal border, suggesting high RV pressure.
    • Rales/Crackles: If pulmonary edema or lung disease is present.

Diagnostic Approach

History Taking

• Key Questions:
  • Perinatal history: Gestational age, birth weight, Apgar scores, mode of delivery, maternal medical conditions (e.g., diabetes, NSAID use).
  • Postnatal course: Respiratory support (FiO2, ventilation), duration of hospitalization, previous diagnoses (e.g., BPD, CDH, CHD).
  • Feeding history: Intake, weight gain, emesis, difficulty with feeds.
  • Growth trajectory: Plotting weight, length, head circumference.
  • Respiratory symptoms: Onset, progression, triggers, severity (tachypnea, retractions, cyanosis, exercise intolerance if applicable to older infants).
  • Cardiac symptoms: Lability of SpO2, episodes of pallor/cyanosis, syncope (rare).
  • Family history: Sudden death, congenital heart disease, connective tissue disorders, unexplained bleeding/clotting disorders.
  • Medication history: Current and recent medications.
  • Developmental milestones: Any delays.
• Red Flags:
  • Persistent cyanosis or SpO2 lability despite maximal oxygen support.
  • Deterioration in respiratory or cardiac status.
  • Evidence of systemic hypotension or shock.
  • Signs of right heart failure (hepatomegaly, edema).
  • Failure to respond to initial therapies for respiratory distress.

Laboratory Tests

• First-Line:
  • Arterial Blood Gas (ABG): To assess oxygenation, ventilation, and acid-base status. Hypoxemia and acidosis can worsen PH.
  • Complete Blood Count (CBC): To rule out anemia (can worsen hypoxemia) or polycythemia (risk of hyperviscosity).
  • Electrolytes, Renal Function Tests (RFTs), Liver Function Tests (LFTs): To assess end-organ function, especially with RV failure.
  • Brain Natriuretic Peptide (BNP) or N-terminal pro-BNP (NT-proBNP): Elevated levels suggest myocardial stretch and dysfunction, particularly RV strain. Levels correlate with severity and prognosis. Reference values vary by age; generally, >100 pg/mL (BNP) or >450 pg/mL (NT-proBNP) in infants are concerning.
  • Blood culture/Sepsis workup: If infection is suspected as a trigger or complicating factor.
• Confirmatory:
  • Genetic testing: If idiopathic/heritable PAH is suspected, or syndromic features are present (e.g., BMPR2 mutations for HPAH, specific genes for ACD/MPV).
  • Viral studies: RSV, adenovirus, metapneumovirus, etc., if viral-induced PH is suspected.
• Monitoring:
  • Repeated ABGs, lactate levels: To assess acute changes in oxygenation, perfusion, and response to therapy.
  • Serial BNP/NT-proBNP levels: To monitor disease progression and response to treatment.
  • CBC: To monitor for anemia or polycythemia.

Imaging

• Recommended:
  • Chest X-ray (CXR):
    • Assess lung parenchyma (pneumonia, BPD changes, hypoplasia).
    • Evaluate cardiac size and shape (cardiomegaly, prominent pulmonary artery segment).
    • Assess pulmonary vascular markings (increased flow in shunts, prune-like in severe PH).
    • Identify diaphragmatic abnormalities (e.g., CDH).
  • Echocardiography (ECHO): The cornerstone of non-invasive PH diagnosis and monitoring.
    • Estimation of pulmonary arterial pressure: Based on tricuspid regurgitation (TR) jet velocity (modified Bernoulli equation), ventricular septal bowing, and RV size/function.
    • Assessment of RV size, function, and hypertrophy: Crucial for evaluating PH severity and prognosis.
    • Detection of congenital heart defects: Shunts (VSD, ASD, PDA), outflow tract obstructions, complex CHD.
    • Evaluation of left heart structure and function: Rule out left heart disease as a cause of PH.
    • Assessment of pulmonary vein drainage: Rule out total anomalous pulmonary venous return (TAPVR).
    • Measurement of pulmonary artery dimensions: Main PA, branch PAs.
• Advanced:
  • Cardiac Catheterization: Gold standard for definitive diagnosis and assessment of PH severity, vasoreactivity, and specific etiology.
    • Direct measurement of pulmonary arterial pressures (mPAP, sPAP, dPAP), pulmonary capillary wedge pressure (PCWP), systemic pressures, and cardiac output.
    • Calculation of Pulmonary Vascular Resistance Index (PVRi).
    • Vasoreactivity testing: Administration of acute vasodilators (e.g., inhaled nitric oxide, iloprost, oxygen) to assess reversibility of PH. A positive response (≥20% fall in mPAP and PVR with preserved/increased cardiac output) is a favorable prognostic sign, guiding treatment.
    • Identification of shunts: Oximetry run, angiogram.
    • Biopsy: Rarely performed in infants.
  • Chest CT Angiography (CTA) or MRI:
    • Detailed assessment of pulmonary vasculature (e.g., stenosis, hypoplasia, anomalous vessels, pulmonary vein stenosis).
    • Evaluation of lung parenchyma for interstitial lung disease or other abnormalities not clear on CXR.
    • Rule out extrinsic compression of pulmonary arteries or airways.
  • Ventilation-Perfusion (V/Q) Scan: Rarely used in infants, mainly to rule out chronic thromboembolic disease if suspected.

Management

Acute Management

• Immediate (PPHN focus):
  • Ensure adequate oxygenation and ventilation: Maintain SpO2 90-95% (target saturation may vary based on clinical context, e.g., higher for systemic perfusion, lower for preventing hyperoxia in susceptible infants like those with BPD).
  • Stabilize systemic blood pressure: Maintain adequate systemic perfusion pressure to support the RV and minimize right-to-left shunting. Use volume resuscitation (10-20 mL/kg boluses of crystalloids) or vasopressors (e.g., dopamine 5-20 mcg/kg/min, norepinephrine 0.05-0.3 mcg/kg/min) if needed.
  • Correct acidosis: Via adequate ventilation or bicarbonate (if severe acidosis).
  • Sedation: To minimize agitation and improve ventilation (e.g., fentanyl 1-4 mcg/kg/hr or midazolam 0.1-0.2 mg/kg/hr).
  • Early inhaled Nitric Oxide (iNO): Often started at 20 ppm. iNO is a selective pulmonary vasodilator. Response is monitored by SpO2 and blood pressure.
• Stabilization:
  • Mechanical Ventilation: If respiratory failure persists. Goals are to normalize CO2 and optimize lung volumes without overdistension. High-frequency oscillatory ventilation (HFOV) may be used in severe cases to achieve lung recruitment and reduce lung injury.
  • Surfactant administration: If there is evidence of surfactant deficiency (e.g., respiratory distress syndrome).
  • Targeted PH Therapies: Beyond iNO, consider starting oral or IV agents for severe or persistent PH (e.g., sildenafil via NG/IV route).
• Emergency:
  • Extracorporeal Membrane Oxygenation (ECMO): Considered for infants with severe refractory PPHN despite maximal conventional and iNO therapy, when PH is reversible and other organ systems are stable.

Chronic Management

• Pharmacological:
  • Oxygen therapy: Cornerstone for chronic PH, especially in lung disease-associated PH. Target SpO2 typically >92-95% (individualize to avoid hyperoxia in certain conditions like BPD).
  • Targeted Pulmonary Arterial Hypertension (PAH) Therapies: Based on WHO Group 1 classification, often initiated after cardiac catheterization and vasoreactivity testing.
    • Phosphodiesterase-5 (PDE5) Inhibitors:
      • Sildenafil: Oral or IV. Dosage: Often 0.5-2 mg/kg/dose PO/IV every 6-8 hours. Start low and titrate up. Important: Risk of pulmonary hypertensive crisis on withdrawal.
      • Tadalafil: Less used in infants, longer half-life.
    • Endothelin Receptor Antagonists (ERAs):
      • Bosentan: Oral. Dosage: Typically 2 mg/kg/dose PO twice daily. Liver function monitoring required.
      • Macitentan: Limited data in infants.
    • Prostacyclin Analogues: Potent vasodilators.
      • Inhaled Iloprost: Dosage: 2.5-5 mcg per inhalation via nebulizer 6-9 times daily.
      • Treprostinil: Subcutaneous, inhaled, or IV. IV infusion is continuous and requires central venous access; Dosage: Titrated from initial 10 ng/kg/min, then carefully escalated.
      • Epoprostenol: Continuous IV infusion. Dosage: Initiated at 2 ng/kg/min and slowly titrated. Highest risk, requires central access and strict adherence.
    • Soluble Guanylate Cyclase (sGC) Stimulators:
      • Riociguat: Limited data in infants.
  • Diuretics: For fluid retention due to right heart failure (e.g., furosemide 1-2 mg/kg/dose PO/IV every 8-12 hours).
  • Digoxin: May be considered for RV dysfunction with persistent low cardiac output, although its role is limited in severe PH (0.01-0.02 mg/kg/day divided in two doses, after loading).
  • Anticoagulation: Generally not routinely used in infants unless there is a specific risk factor for thrombosis (e.g., central line, severe PAH). Low-molecular-weight heparin (e.g., enoxaparin 0.75 mg/kg SC q12h) may be considered.
• Non-pharmacological:
  • Nutritional support: High-calorie formula/breast milk fortification, nasogastric or gastrostomy tube feeding to support growth and reduce metabolic burden.
  • Infection prevention: Aggressive management of respiratory infections, immunizations (influenza, RSV prophylaxis with palivizumab for eligible infants).
  • Avoidance of triggers: Hypoxia, acidosis, cold exposure, high altitude.
  • Physical activity: Judiciously encouraged once stable, within tolerance limits (avoid excessive exertion).
  • Psychosocial support: For families dealing with chronic illness.
  • Referral to specialized PH center: Essential for comprehensive care.
• Monitoring:
  • Clinical assessment: Regular evaluation of symptoms, growth, exercise tolerance (if applicable).
  • Pulse oximetry: Continuous or spot checks.
  • Echocardiography: Every 3-6 months, or more frequently if clinically indicated, to assess RV function and estimated PA pressures.
  • BNP/NT-proBNP: Periodically, to assess disease severity and response to therapy.
  • Liver function tests: Regularly, especially with ERAs.
  • Right heart catheterization: Periodically, often every 1-2 years, to reassess hemodynamics and guide therapy adjustments, especially if clinical deterioration or new symptoms.
  • Developmental assessment: Regular screening and intervention for developmental delays.

Treatment Algorithms

• First-Line (PPHN):
  1. Stabilization: Oxygen, ventilation, correction of acidosis/hypotension.
  2. Inhaled Nitric Oxide (iNO): Starting dose usually 20 ppm, titrated down.
  3. Surfactant (if lung disease).
  4. Consider high-frequency ventilation.
  5. If refractory, consider ECMO.
• First-Line (Chronic PAH - WHO Group 1):
  1. General supportive measures: Oxygen, nutritional support, immunizations.
  2. Referral to specialized PAH center.
  3. Right heart catheterization with vasoreactivity testing: To confirm diagnosis, assess severity, and guide therapy.
  4. Initiate targeted PAH therapy:
     • Non-vasoreactive: Combination therapy is increasingly favored. Often starts with an ERA (e.g., bosentan) and a PDE5 inhibitor (e.g., sildenafil).
     • Vasoreactive: May initially be treated with a calcium channel blocker (e.g., nifedipine, amlodipine), but careful monitoring is required due to side effects and limited efficacy in severe PH. Most infants are not truly sustained vasoreactors.
• Second-Line (Chronic PAH):
  1. Sequential addition of medications: If response to initial therapy is suboptimal (e.g., adding a prostacyclin analogue to ERA + PDE5i).
  2. Switching medications within classes: If side effects or inadequate response (e.g., sildenafil to tadalafil, bosentan to macitentan).
• Refractory Cases:
  1. Triple therapy: Combining an ERA, PDE5i, and prostacyclin analogue (often IV treprostinil or epoprostenol).
  2. Lung transplantation: Definitive therapy for severe, end-stage, refractory PAH, but rarely feasible in infancy due to donor limitations and high risk.
  3. Atrial Septostomy: Palliative procedure to decompress the right ventricle, may improve systemic cardiac output and reduce syncope, but carries risks.

Complications

• Common:
  • Right Ventricular Failure: Due to chronic pressure overload, leading to systemic congestion and reduced cardiac output.
  • Growth failure/Failure to thrive: Due to increased metabolic demand, poor feeding, chronic illness.
  • Recurrent respiratory infections.
  • Hypoxemia: Chronic or acute severe episodes.
• Serious:
  • Pulmonary Hypertensive Crisis: Acute, severe worsening of PH with systemic hypoxemia, hypotension, and RV failure, often triggered by pain, agitation, or medical procedures.
  • Sudden cardiac death: Due to arrhythmias or acute RV failure.
  • Systemic emboli: Particularly if patent foramen ovale (PFO) or ASD with right-to-left shunting is present.
  • Bleeding complications: Especially with prostacyclin use (e.g., central line associated bleeding, GI bleed).
• Long-term:
  • Neurodevelopmental impairment: Especially in survivors of severe PPHN or chronic hypoxemia.
  • Cardiomyopathy: Chronic RV strain can lead to RV dysfunction and dilation.
  • Irreversible pulmonary vascular disease: Fixed and progressive PH despite therapy, often leading to transplant consideration.

Prognosis

• Factors:
  • Underlying etiology: PPHN generally has a better prognosis than chronic forms associated with severe lung disease or idiopathic/heritable PAH. PH secondary to CDH often has a poor prognosis.
  • Severity at diagnosis: Higher initial PA pressures and worse RV function correlate with poorer outcomes.
  • Response to therapy: Vasoreactivity and clinical improvement with targeted therapies are favorable signs.
  • Presence of comorbidities: Especially severe lung disease (BPD) or complex CHD.
  • Early and specialized management: Referral to a center with expertise in pediatric PH is crucial.
  • Sustained growth and nutritional status.
• Survival:
  • PPHN: With modern management, survival rates are 80-90%. Neurological complications are significant in survivors.
  • Chronic PAH: Varies widely based on etiology.
    • Associated with CHD (after repair): Prognosis is often good if PH resolves.
    • Associated with BPD: Can be very challenging, with significant mortality and morbidity.
    • Idiopathic/Heritable PAH: Historically poor, but improved with targeted therapies, 5-year survival rates are improving but still challenging in infancy.
• Quality of Life:
  • Often significantly impacted by chronic symptoms, frequent hospitalizations, medication burden, and developmental delays. Requires comprehensive multidisciplinary support.

Prevention

• Primary: Preventing initial occurrence
  • Optimizing antenatal care: To prevent prematurity, maternal infections, and other risk factors for PPHN.
  • Avoidance of NSAIDs in late pregnancy: Can prematurely close the PDA and increase risk of PPHN.
  • Careful management of labor and delivery: To prevent perinatal asphyxia.
  • Early diagnosis and repair of significant left-to-right shunt CHD: Before irreversible pulmonary vascular changes occur.
• Secondary: Early detection and intervention
  • High index of suspicion for PH in at-risk infants: E.g., those with severe BPD, CDH, or unexplained respiratory symptoms.
  • Routine screening echocardiography: For high-risk populations (e.g., severe BPD, CDH).
  • Early referral to a pediatric cardiology/pulmonology specialist for evaluation of suspected PH.
• Tertiary: Preventing complications
  • Aggressive management of infections: Vaccination, RSV prophylaxis.
  • Optimization of nutrition and growth.
  • Adherence to prescribed PH therapies and regular monitoring.
  • Education of caregivers on signs of worsening PH and emergency protocols.

Special Populations

• Neonates (PPHN): Primary focus of acute management. Key is to stabilize systemic blood pressure, ensure adequate oxygenation, and use iNO. ECMO is a rescue therapy.
• Infants with Congenital Heart Disease (CHD):
  • Pre-repair: Management focuses on balancing systemic and pulmonary blood flow. Timely surgical repair of significant shunts (e.g., large VSDs) is crucial to prevent irreversible PH.
  • Post-repair: PH may persist if pulmonary vascular disease has already developed. Targeted PAH therapies may be needed.
• Infants with Bronchopulmonary Dysplasia (BPD):
  • Often have multifactorial PH (hypoxia, vascular pruning, remodeling).
  • Oxygen therapy is paramount. Diuretics and targeted PAH therapies may be used.
  • Often requires careful ventilation strategies to minimize lung injury.
• Infants with Congenital Diaphragmatic Hernia (CDH):
  • Severe pulmonary hypoplasia and vascular remodeling predispose to severe, often refractory, PH.
  • Aggressive medical management, iNO, and sometimes ECMO are used. Surgery for CDH is typically performed once PH is stabilized.
• Infants with Genetic Syndromes:
  • Down Syndrome: Increased risk of CHD (e.g., AV canal defects) and pulmonary hypertension, often out of proportion to the CHD. May respond differently to therapies.
  • Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACD/MPV): Extremely rare, fatal cause of severe PPHN due to genetic defect. Often refractory to all therapies.
• Comorbidities: Management needs to integrate care for PH with other conditions, considering drug interactions, overall fluid balance, and impact on other organ systems.

Clinical Pearls

• Diagnostic:
  • Always suspect PH in an infant with unexplained hypoxemia or respiratory distress disproportionate to lung disease.
  • Echocardiography is the initial screening tool, but cardiac catheterization is the gold standard for diagnosis and vasoreactivity testing.
  • Lability of oxygen saturation, especially with crying or handling, is a classic sign of PH in infants.
  • Differential cyanosis (pre-ductal vs. post-ductal SpO2 difference >5-10%) strongly suggests PPHN with right-to-left shunting across a PDA.
• Treatment:
  • Oxygen is a pulmonary vasodilator; avoid hypoxemia.
  • Maintain adequate systemic blood pressure to ensure optimal RV perfusion and minimize right-to-left shunting.
  • Avoid acidosis, hypothermia, and hypercapnia, as these can exacerbate PH.
  • When using iNO, titrate carefully and monitor for rebound PH if discontinued abruptly.
  • Sildenafil withdrawal can lead to severe rebound PH; avoid abrupt cessation.
  • Chronic PH management requires a multidisciplinary team and specialized center.
• Pitfalls:
  • Underestimating the severity of PH based solely on echo: Catheterization may reveal higher pressures.
  • Delaying appropriate workup and referral to a specialized center: Can lead to progression of irreversible vascular changes.
  • Abruptly stopping PH medications: Can lead to life-threatening rebound PH crises.
  • Over-oxygenation in infants with chronic lung disease: Can potentially worsen lung injury (e.g., in BPD). Individualized SpO2 targets are critical.
  • Treating only the symptoms (e.g., hypoxemia) without addressing the underlying PH.

Recent Updates

• Guidelines:
  • 2019 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: While primarily adult-focused, these are increasingly being adapted for pediatric practice, emphasizing early combination therapy and risk stratification.
  • Consensus statements from the Pediatric Pulmonary Hypertension Network (PPHN) and other pediatric cardiology/pulmonology societies continue to refine diagnostic and treatment approaches for specific pediatric subgroups (e.g., PH associated with BPD, CDH).
  • Focus on individualized risk assessment and treatment algorithms: Moving beyond "one size fits all" to phenotype-specific approaches.
• Evidence:
  • Growing evidence supporting the benefit of upfront combination therapy for severe PAH in children.
  • Research into novel therapeutic targets and drugs, including prostacyclin receptor agonists (e.g., selexipag) and sGC stimulators (e.g., riociguat), with ongoing trials in pediatric populations.
  • Increased understanding of the genetic basis of pediatric PAH, guiding personalized medicine approaches.
  • Emphasis on the importance of comprehensive neurodevelopmental follow-up for survivors, particularly of severe PPHN and chronic PH.
• Controversies:
  • Optimal timing and indications for right heart catheterization in infants with suspected PH: Balancing diagnostic yield with risks.
  • Role of upfront combination therapy vs. sequential monotherapy in pediatric PAH.
  • Specific oxygen saturation targets in different etiologies of PH (e.g., PPHN vs. BPD-PH).
  • Long-term safety and efficacy of newer targeted therapies in the very young population.

Key References

• Guidelines:
  • American Heart Association/American Thoracic Society Scientific Statement on Pediatric Pulmonary Hypertension. (Regularly updated statements)
  • European Society of Cardiology (ESC)/European Respiratory Society (ERS) Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. (2019 and subsequent updates, with pediatric sections or adaptations)
  • Pediatric Pulmonary Hypertension Network (PPHN) Consensus Statements.
• Studies:
  • NECTARINE Study (NCT03024507) - A study of macitentan in pediatric PAH.
  • STARTS-2 Study - Long-term extension trial for sildenafil in pediatric PAH.
  • Published cohort studies and registries from major pediatric PH centers contributing to understanding natural history and treatment outcomes.
• Reviews:
  • UpToDate: Pulmonary Hypertension in Infants and Children: Management, Prognosis, and Evaluation.
  • Journal of the American College of Cardiology (JACC) State-of-the-Art Review: Pediatric Pulmonary Hypertension.
  • Pediatric Pulmonology (Journal) - Special issues on PH.